Gene therapy to improve migration of T cells to the tumor site.

Academic Article


  • One requirement for anti-tumor T cells to be effective is their successful traffic to tumor sites. Trafficking of T cells to lymphoid organs and peripheral tissues is a multistage process. Soluble and tissue-bonded chemokines interacting with chemokine receptors expressed by T lymphocytes certainly play a pivotal role in determining migration under physiologic conditions and during inflammation. Therefore a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express is required. Since chemokine produced by the targeted tumor may not match the subset of chemokine receptors expressed by T cells, gene therapy can be used to force the expression of the specific chemokine receptor by effector T cells so that the anti-tumor activity of adoptively transferred anti-tumor T cells is maximized.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Di Stasi A; De Angelis B; Savoldo B
  • Start Page

  • 103
  • End Page

  • 118
  • Volume

  • 651